Iovance Biotherapeutics Inc (IOVA)
NASDAQ:IOVA
IOVA Stock Chart & Stats
$3.51
-$0.33(-4.53%)
At close: 4:00 PM EST
$3.51
-$0.33(-4.53%)
Day’s Range― - ―
52-Week Range$1.64 - $5.63
Previous CloseN/A
Volume2.95M
Average Volume (3M)18.82M
Market Cap
$1.37B
Enterprise Value$1.05B
Total Cash (Recent Filing)$296.98M
Total Debt (Recent Filing)$48.44M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
May 07, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding411,961,600
10 Day Avg. Volume11,525,365
30 Day Avg. Volume18,815,498
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.40
Price to Sales (P/S)3.70
P/FCF Ratio-2.90
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue3.98
Enterprise Value/Gross Profit4.10
Enterprise Value/Ebitda-2.91
Forecast
1Y Price Target
$8.00Price Target Upside127.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)-0.51
Revenue Forecast (FY)$381.84M
Bulls Say, Bears Say
Bulls Say
Clinical Real-world ValidationAnalyst points to real-world data showing AMTAGVI delivers meaningful antitumor benefit and higher response rates earlier in treatment, which supports broader market access and uptake.
Manufacturing And MarginsAnalyst notes that improved manufacturing processes and better patient use have raised gross margins, enhancing the company's profitability potential as volume scales.
Regulatory MilestoneAnalyst highlights that a regulatory filing in non-small cell lung cancer could enable an additional product launch and materially broaden the company's commercial footprint.
Bears Say
Investor SentimentInvestor skepticism about the tumor-infiltrating lymphocyte strategy and demand for confirmatory melanoma results may limit buying interest and weigh on the stock.
Revenue Forecast RiskAnalyst reduced sales expectations for AMTAGVI, creating downside risk to revenue forecasts and valuation assumptions.
Share Dilution RiskAnalyst cautions that increases in share count could create dilution pressure that reduces per-share earnings and investor returns.
Iovance Biotherapeutics News
IOVA FAQ
What was Iovance Biotherapeutics Inc’s price range in the past 12 months?
Iovance Biotherapeutics Inc lowest stock price was $1.64 and its highest was $5.63 in the past 12 months.
What is Iovance Biotherapeutics Inc’s market cap?
Iovance Biotherapeutics Inc’s market cap is $1.37B.
When is Iovance Biotherapeutics Inc’s upcoming earnings report date?
Iovance Biotherapeutics Inc’s upcoming earnings report date is May 07, 2026 which is in 35 days.
How were Iovance Biotherapeutics Inc’s earnings last quarter?
Iovance Biotherapeutics Inc released its earnings results on Feb 24, 2026. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of -$0.175 by -$0.005.
Is Iovance Biotherapeutics Inc overvalued?
According to Wall Street analysts Iovance Biotherapeutics Inc’s price is currently Undervalued.
Does Iovance Biotherapeutics Inc pay dividends?
Iovance Biotherapeutics Inc does not currently pay dividends.
What is Iovance Biotherapeutics Inc’s EPS estimate?
Iovance Biotherapeutics Inc’s EPS estimate is -0.14.
How many shares outstanding does Iovance Biotherapeutics Inc have?
Iovance Biotherapeutics Inc has 411,961,600 shares outstanding.
What happened to Iovance Biotherapeutics Inc’s price movement after its last earnings report?
Iovance Biotherapeutics Inc reported an EPS of -$0.18 in its last earnings report, missing expectations of -$0.175. Following the earnings report the stock price went up 30.796%.
Which hedge fund is a major shareholder of Iovance Biotherapeutics Inc?
Currently, no hedge funds are holding shares in IOVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Iovance Biotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (127.92% Upside)
$8.00 (127.92% Upside)
Blogger Sentiment
Bullish
IOVA Sentiment 85%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 152.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 6.4%
Last 30 Days ▲ 6.4%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.74%
12-Months-Change
Fundamentals
Return on Equity
-54.54%
Trailing 12-Months
Asset Growth
0.30%
Trailing 12-Months
Company Description
Iovance Biotherapeutics Inc
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
IOVA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial commercial and operational momentum: strong revenue growth (Q4 $87M; FY $264M), sharp YoY growth in Amtagvi (112%), best-ever Q4 gross margin (50%), manufacturing internalization, extended cash runway to Q3 2027, regulatory progress (fast-track for lifileucel in NSCLC) and very encouraging early sarcoma signals (50% ORR in 6 evaluable patients). Offsetting these positives are outstanding execution risks — limited 2026 guidance at the time of the call, a cash runway that will require continued improvement or financing before Q3 2027, small sample size for the sarcoma data, ongoing enrollment and regulatory timing risk for registrational programs, and some dependence on distributor ordering dynamics. Overall, the highlights materially outweigh the lowlights, but continued execution on enrollment, approvals, margin improvements and cash management will be critical.View all IOVA earnings summariesIOVA Stock 12 Month Forecast
Average Price Target
$8.00
▲(127.92% Upside)
Technical Analysis
KalVista Pharmaceuticals
―
Vir Biotechnology
―
Immatics
―
Nuvation Bio
―
Amylyx Pharmaceuticals Inc
―
Ownership Overview
0.35% Insiders
11.55% Mutual Funds
18.14% Other Institutional Investors
55.20% Public Companies and Individual Investors